BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Sean McCarthy to moderate panel, "Bridges Over Troubled Water and M&A "a la carte": Financing and Exiting", at Bio 2010 in Chicago, IL
News | 05. 05. 2010
